|
|
|
|
Advanced Guidance Systems, LLC
 |
Description |
|
Guide View System |
UT Faculty Involved |
|
M. Sriram Iyengar, Ph.D |
Location |
|
Houston, TX |
Year Formed |
|
|
Other Information |
|
Software related to a system for developing and delivering structured, interactive, multi-modal guidelines with a versatile interdisciplinary application and means of employment. |
 |
| |
Ampholife Technologies, Inc. |
Description |
|
Large-scale purification of biological materials |
UT Faculty Involved |
|
L. Scott Rodkey |
Location |
|
Houston, TX |
Year Formed |
|
1988 |
Other Information |
|
Currently manufactures the ATIsolator, a high-volume protein purification instrument that utilizes a fluid-phase isoelectric focusing format for high-resolution preparative purification of biomolecules and manufactures a series of ampholyte compounds.
|
|
|
Description
| Cerevast Therapeutics, Inc. is a life sciences company with primary emphasis in the field of sonolysis for the treatment of vascular thrombus disorders. Based on technology created by Dr. Andrei Alexandrov, Cerevast plans to market a patented, innovative, operator-assisted transcranial doppler (TCD) ultrasound device with an initial therapeutic focus in the field of acute ischemic stroke. The company plans to leverage the unique geometry of the TCD device in combination with thrombolytics or proprietary microsphere technology as a non-invasive therapy for disrupting blood clots and restoring blood flow in the vasculature of the brain.
|
|
| |
|
Description |
|
Medical Device - Dematology - Cryosurgery CryoPen Surgical System - Linear compression cooling technology, does not require handling of dangerous cryogenic gases - penpoint precision and socnistent freeze temperature reduces the risk of burns.
|
|
Location |
|
Corpus Christi, Tx
|
| |
|
Endothelix, Inc
 |
Description |
|
Monitoring technology for cardiovascular health |
Location |
|
Houston, TX |
Year Formed |
|
2003 |
Other Information |
|
Endothelix was awarded a $1 million grant from the State of Texas Emerging Technologies Fund for the development of its VENDYS™ system, for the measurement of vascular reactivity, and endothelial dysfunction. Recently VENDYS™ was approved by the FDA for commercial sale.
|
|
|
|
|
EMIT Corporation |
Description |
|
EMIT Corporation (Emergency Medical Interventional Technologies Corporation) is developing trauma care products based on innovative devices developed by UTHSC-H’s Drs. Charles Cox, Jr. and Brijesh Gill from the Departments of Pediatric Surgery and Surgery, respectively. EMIT’s first product includes a novel, patent-protected, portable fluid warmer to deliver therapeutic temperature management to patients experiencing hypothermia anywhere in the world and much sooner after injury. |
IsoVax Therapeutics |
Description |
|
IsoVax Therapeutics is an early stage, drug-discovery biotech company involved in the identification and production of conformational protein isomers of important proteins involved in the diagnosis and/or treatment of disease which are unique targets for developing diagnostic and therapeutic antibodies and vaccines. |
|
 |
Description |
|
Multi-stage nanovector drug delivery technology to facilitate chemotherapy and biological anti-cancer agent delivery |
| |
Year Formed |
|
2008 |
| |
UT Faculty Involved |
|
Mauro Ferrari, Ph.D. |
| |
Location |
|
Pasadena, CA |
| |
Year Formed |
|
2007 |
|
Other Information |
|
The Company’s first target market is drug refractory breast cancer. |
|
|
|
|
|
Description |
|
Biologically-based products for the repair and replacement of human tissue
|
UT Faculty Involved |
|
Dr. John Linner |
Location |
|
Branchburg, NJ |
Year Formed |
|
1986 |
|
Other Information |
|
LifeCell’s current products include ALLODERM®, a regenerative tissue matrix, for plastic reconstruction. LIFC had an IPO in 1992, and in 2008, projected revenues are estimated at $233.0 million. LIFC recently announced its acquisition by Kinetics Concepts Inc. for $1.7 billion.
|
|
|
|
|
|
Marval Biosciences, Inc.
 |
Description |
|
Marval Biosciences, Inc. is developing the next generation contrast agents for high speed, high resolution CT scanners. |
UT Faculty Involved |
|
Ananth Annapragada |
Location |
|
|
Year Formed |
|
2007 |
Other Information |
|
Marval’s agents remain in the circulation for hours, facilitating continuous follow-up imaging in patients with evolving vascular crises including myocardial infarcts, stroke, and pulmonary emboli. Series A funding of $1.4 Million as well as SBIR Phase II funding from the NIH. |
|
NanoMedical Systems, Inc.
|
Description |
|
Nano-engineered diffusion delivery systems for drug delivery. Personalized Molecular Drug delivery System (PMDS) is a small drug delivery device that is implanted under the skin for slow and consistent release of a therapeutic agent over many weeks or months. A non channel delivery system (nDS) embodied on a silicon chip regulates the flow of therapeutic molecules.
|
UT Faculty Involved |
|
Mauro Ferrari, Ph.D. |
Location |
|
Austin, TX |
Year Formed |
|
2008 |
Other Information |
|
NanoMedical Systems (NMS) is one of the first convergent technology companies, integrating semiconductor, biotechnology, MEMS/NEMS, nano-materials, and pharmaceutical sciences in its products. Operates in the drug delivery field. |
|
PLx Pharma, Inc.
|
|
|
|
Description |
|
PC-NSAID based medications used for pain, inflammation, and cardiovascular treatment |
UT Faculty Involved |
|
Leonard Lichtenberger |
Location |
|
Houston, TX |
Year Formed |
|
2002 |
Other Information |
|
PLx completed four clinical trials with two lead products, and a third product recently received IND approval. PLx raised over $11 million, and has sponsored $4M in research to UTHSC-H and UT Medical Branch.
|
|
| |
|
|
|
Protein Institute Inc. (Isovax)
|
Description |
|
Protein identification for disease, diagnosis/treatment |
| |
UT Faculty Involved |
|
Rowen Chang |
| |
Location |
|
Houston, TX |
| |
Year Formed |
|
2001 |
| |
Other Information |
|
PII possesses a series of biologically significant protein structural isomer profiles, which may lead to the development of new therapeutics and/or diagnostics for CNS diseases and cytokine disorders.
|
|
|
Simulation Education Services, Inc. |
Description |
|
Web-based disaster exercise technology |
UT Faculty Involved |
|
Scott Lillibridge |
Location |
|
Des Moines, IA |
Year Formed |
|
2006 |
Other Information |
|
SES’s technology targets health care responders and other vital response sectors in areas where they have health related responsibilities, such as law enforcement, EMS, fire services, preparedness training in bioterror, mass casualty, natural disaster, and pandemic flu. SES webinars feature nationally known speakers dealing with topics pertinent to the disaster preparedness community to provide exercises and assessment needs.
|
|
Telemedicus, Inc.
|
Description |
|
Products for fixed, mobile and deployable telemedicine applications that effectively places a “virtual physician” at a remote location. |
UT Faculty Involved |
|
James "Red" Duke, Doug Tindall |
Location |
|
Houston, TX |
Year Formed |
|
2006 |
Other Information |
|
Telemedicus, Inc. targets a market of 40,000 ambulances nationwide, as well as emergency care facilities and remote or dislocated medical facilities. The Telemedicus technology operated in New Orleans after Katrina and is in operation in Houston and in Liberty Counties. |
|
TexTeach, Inc. |
Description |
|
Care of Aging Videos for Nurse training |
|
UT Faculty Involved |
|
Nancy Bergstrom and Vaunette Fay |
Location |
|
Houston, TX |
Year Formed |
|
2005 |
Other Information |
|
Two products on the market |
|
|
|
|
Vanjan, Inc.
|
Description |
|
Novel treatment to control mycobacterium tuberculosis infections (MTB). |
UT Faculty Involved |
|
Dr. James Stoops |
Location |
|
Houston, TX |
Year Formed |
|
2007 |
Other Information |
|
Vanjan’s novel treatment is ideal for use in third world countries because of the inexpensive cost. Vanjan is currently beginning clinical trials to test treatment efficacy. |
|
|
Description |
|
Cardiology medical devices for the diagnosis and treatment of coronary plaque |
UT Faculty Involved |
|
James T. Willerson and Ward S. Casscells |
Location |
|
Rancho Cordova, CA |
Year Formed |
|
2001 |
Other Information |
|
Volcano Inc. specializes in the manufacture of intravascular ultrasound and other devices for use in the assessment of heart and vascular disease. Volcano had an Initial Public Offering (IPO) in June 2006, based, in part, on the value of UTHSC-H technology. |
|
Windmill Cardiovascular Systems, Inc
 |
Description |
|
Left ventricular assist device and a total artificial heart |
|
UT Faculty Involved |
|
Richard Smalling |
|
Location |
|
Austin, TX |
|
Year Formed |
|
2005 |
|
Other Information |
|
The WCS blood pump, TORVADTM, eliminates inlet and outlet valves while providing capability for control and synchronization with the native heart over a wide range of blood flows from near steady flow to pulsatile flow. WCS raised over $1.7 million with a commitment of approx. $3 million through 2010. |
|
Your Doctor Program, Inc.
|
Description |
|
Patient outcomes management system |
UT Faculty Involved |
|
Kim Dunn |
Location |
|
Houston, TX |
Year Formed |
|
2001 |
Other Information |
|
Involves numerous local, state, and national organizations
|
